Schistosomiasis Translation Platform

We are working with partners to evaluate the translational aspects of potential new treatments for schistosomiasis with a focus on establishing a schistosomiasis ‘compound box’ to be made available to researchers for testing. The platform is assessing a well-characterized compound library assembled by Merck through a series of in vitro and in vivo assays. Subsequent pharmacokinetic/pharmacodynamic (PK/PD) analyses will provide insights into pre-clinical and clinical translation and help identify drivers of efficacy. The project’s aim is to contribute to global schistosomiasis drug discovery efforts and facilitate a better understanding of how in vitro activity translates into in vivo efficacy and, ultimately, clinical relevance.